Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

Investor Relations

Copyright West LLC. Minimum 15 minutes delayed.

News Releases
May 14, 2020
electroCore Announces First Quarter Financial Results
Generated first quarter revenue of $734,000 Secured FDA clearance of gammaCore ™ (nVNS) label expansion for migraine prevention Announced initiatives to support the potential use of nVNS for the treatment of symptoms associated with COVID-19 Company to host conference call and webcast today, May
April 27, 2020
electroCore Provides Update on COVID-19 Clinical Initiatives
Randomized controlled investigator-initiated trial (IIT) of non-invasive vagus nerve stimulation (nVNS) therapy currently enrolling COVID-19 patients in Spain Peer-reviewed paper, “Use of Non-Invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated with COVID-19: A Theoretical

Investor Contact

Investor Relations

Hans Vitzthum, LifeSci Advisors
investors@electrocore.com